Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis (Q31406106)

2 July 2017

1 reference

title

Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis (English)

1 reference

2 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

Goldenberg MM

1

1 reference

2 July 2017

1 November 1999

1 reference

2 July 2017

Clinical Therapeutics

1 reference

2 July 2017

21

1 reference

2 July 2017

11

1 reference

2 July 2017

1837-52; discussion 1821

1 reference

Survival, prognosis, and causes of death in rheumatoid arthritis

2 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Early rheumatoid arthritis--some social, economical, and psychological aspects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Management of adverse effects of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Cyclosporin A inhibits autoimmune experimental tubulointerstitial nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2986732-6

7 January 2021

10.1016/S0149-2918(00)86732-6

Identifiers

DOI

1 reference

2 July 2017

1 reference

PubMed ID

10890256